Literature DB >> 19444573

Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis.

Jun Oto1, Kenichi Suga, Sato Matsuura, Shuji Kondo, Yoshiaki Ohnishi, Daisuke Inui, Hideaki Imanaka, Shoji Kagami, Masaji Nishimura.   

Abstract

Focal segmental glomerulosclerosis (FSGS) often leads to refractory nephrotic syndrome (NS). A high level of low-density lipoprotein (LDL) is a risk factor for the progression of NS. An 8-year-old girl presented with severe proteinuria refractory to steroid therapy. She was diagnosed with non-IgA diffuse mesangial proliferative glomerulonephritis. Oral prednisolone, methylprednisolone (mPL) pulse therapy, and cyclosporine and cyclophosphamide therapy failed to achieve remission. Follow-up renal biopsy revealed FSGS. Her serum level of LDL was high, and LDL-apheresis (LDL-A) was performed five times, followed by mPL pulse therapy. Urinary protein decreased from 2-4 g x day(-) to 0.5-1.0 g x day(-). LDL-A may be beneficial in the treatment of multidrug-resistant FSGS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444573     DOI: 10.1007/s00540-008-0726-z

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  13 in total

1.  Treatment of primary focal segmental glomerulosclerosis.

Authors:  Stephen M Korbet
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

2.  Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).

Authors:  K Tojo; S Sakai; T Miyahara
Journal:  Nihon Jinzo Gakkai Shi       Date:  1988-09

3.  Primary focal segmental glomerulosclerosis in children: prognostic factors.

Authors:  R Martinelli; A S Okumura; L J Pereira; H Rocha
Journal:  Pediatr Nephrol       Date:  2001-08       Impact factor: 3.714

4.  Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy.

Authors:  Tsukasa Nakamura; Yasuhiro Kawagoe; Hiroshi Ogawa; Yoshihiko Ueda; Masanori Hara; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

5.  LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy.

Authors:  K Yokoyama; S Sakai; T Sigematsu; F Takemoto; S Hara; A Yamada; Y Kawaguchi; T Hosoya
Journal:  Clin Nephrol       Date:  1998-07       Impact factor: 0.975

6.  A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.

Authors:  Motoshi Hattori; Hiroko Chikamoto; Yuko Akioka; Hyogo Nakakura; Daisuke Ogino; Akira Matsunaga; Akira Fukazawa; Sanpei Miyakawa; Miyuki Khono; Hiroshi Kawaguchi; Katsumi Ito
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

Review 7.  Primary focal segmental glomerulosclerosis: clinical course and response to therapy.

Authors:  S M Korbet; M M Schwartz; E J Lewis
Journal:  Am J Kidney Dis       Date:  1994-06       Impact factor: 8.860

8.  Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?

Authors:  E Muso; M Yashiro; M Matsushima; H Yoshida; K Sawanishi; S Sasayama
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

Review 9.  Applications of LDL-apheresis in nephrology.

Authors:  Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

10.  Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks.

Authors:  C Stefanutti; A Lanti; S Di Giacomo; M Mareri; F De Lorenzo; A Landolfo; G Isacchi
Journal:  Transfus Apher Sci       Date:  2004-08       Impact factor: 1.764

View more
  4 in total

Review 1.  An update on LDL apheresis for nephrotic syndrome.

Authors:  Rupesh Raina; Vinod Krishnappa
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

2.  Successful treatment by mycophenolate mofetil in a patient with focal segmental glomerulosclerosis associated with posterior reversible encephalopathy syndrome.

Authors:  Masafumi Tenta; Haruhito Adam Uchida; Tomokazu Nunoue; Ryoko Umebayashi; Yuka Okuyama; Masashi Kitagawa; Yohei Maeshima; Hitoshi Sugiyama; Jun Wada
Journal:  CEN Case Rep       Date:  2014-12-30

3.  Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study.

Authors:  Rupesh Raina; Vinod Krishnappa; Cheryl Sanchez-Kazi; Alejandro Quiroga; Katherine E Twombley; Robert Mathias; Megan Lo; Ronith Chakraborty; Shefali Mahesh; Julia Steinke; Timothy Bunchman; Joshua Zaritsky
Journal:  Front Pediatr       Date:  2019-12-03       Impact factor: 3.418

4.  Association of apoE gene polymorphisms with lipid metabolism in renal diseases.

Authors:  Tianbiao Zhou; Hongyan Li; Hongzhen Zhong; Zhiqing Zhong; Shujun Lin
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.